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Abstract
miRNAs are essential for self-renewal and differentiation of normal and malignant stem cells by 
regulating the expression of key stem cell regulatory genes. Here, we report evidence implicating 
the miR100 in self-renewal of cancer stem-like cells (CSC). We found that miR100 expression 
levels relate to the cellular differentiation state, with lowest expression in cells displaying stem 
cell markers. Utilizing a tetracycline-inducible lentivirus to elevate expression of miR100 in 
human cells, we found that increasing miR100 levels decreased the production of breast CSCs. 
This effect was correlated with an inhibition of cancer cell proliferation in vitro and in mouse 
tumor xenografts due to attenuated expression of the CSC regulatory genes SMARCA5, 
SMARCD1, and BMPR2. Furthermore, miR100 induction in breast CSCs immediately upon their 
orthotopic implantation or intracardiac injection completely blocked tumor growth and metastasis 
formation. Clinically, we observed a significant association between miR100 expression in breast 
cancer specimens and patient survival. Our results suggest that miR100 is required to direct CSC 
self-renewal and differentiation.
Introduction
There is increasing evidence that cancer stem cells (CSC) are resistant to chemotherapy and 
radiotherapy and, thus, may contribute to treatment resistance and relapse. The development 
and validation of breast cancer stem cell (BCSC) biomarkers, including CD24− CD44+, 
aldehyde dehydrogenase (ALDH), and assays including mammosphere formation and 
xenograft models by our laboratory and others (1–4) has facilitated studies demonstrating 
the relative resistance of BCSCs to radiation and chemotherapy.
Until recently, the function of noncoding regions of the genome was unknown. However, it 
is now clear that many of these regions code for miRNAs. Each miRNA is capable of 
regulating the expression of multiple proteins and, as a result, can have very potent effects 
on cellular functions. miRNAs mediate gene silencing through imperfect hybridization to 3′ 
untranslated regions (3′ UTR) in target mRNAs (5) and modulate a variety of cellular 
processes, including the regulation of mRNA stability and translation, cellular proliferation, 
and apoptosis (6). Many studies have demonstrated a link between dysregulated expression 
of miRNAs and carcinogenesis (7, 8). Emerging evidence demonstrates that miRNAs also 
play an essential role in stem cell self-renewal and differentiation by regulating the 
expression of certain key stem cell regulatory genes (9–12).
The Drosophila let-7-complex is a polycistronic locus encoding three ancient miRNAs: Let7, 
miR100, and fly lin-4 (mir25), which are cotranscribed as a single polycistronic transcript 
(13). These three miRNAs coordinately control gene expression to regulate developmental 
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processes (13). It has been shown that miR100 is downregulated in ovarian cancer (14, 15), 
hepatocellular carcinomas (16), and head and neck squamous cell carcinoma (HNSCC; refs. 
17, 18). Lower expression of let7 and mir-100 were significantly correlated with a poor 
prognosis in ovarian cancer (14). Gollin and colleagues reported that the let7-mir-100-mir25 
cluster is located in intron 2 at chromosome 11q24 (19), and the downregulation of miR100 
in HNSCC plays an important role in the development and/or progression of disease as well 
as contributing to resistance to radiotherapy (19). In mouse xenografts, expression of 
miR100 completely blocks tumor growth and metastasis. Our findings suggest that miR100 
plays an important role in the regulation of BCSCs.
Materials and Methods
Cell culture
Breast cancer cell line SUM159 and SUM149 were from Asterland (20). MCF-7, T47D, and 
HCC1954 were purchased from ATCC. The culture medium for SUM159 and SUM149 is 
Ham F-12 (Invitrogen) supplemented with 5% FBS, 5 µg/mL insulin, and 1 µg/mL 
hydrocortisone (both from Sigma). MCF7, T47D, and HCC1954 cells were maintained in 
RPMI1640 medium (Invitrogen) supplemented with 10% FBS (ThermoFisher Scientific), 
1% antibiotic-antimycotic (Invitrogen), and 5 µg/mL insulin (Sigma-Aldrich). All cell lines 
were recently obtained from ATCC or Asterland when the experiments were performed and 
their identity is routinely monitored by STR profiling.
Tumorigenicity in NOD/SCID mice
All NOD/SCID mice were bred and housed in Association for Assessment and 
Accreditation of Laboratory Animal Care-accredited specific pathogen-free rodent facilities 
at the University of Michigan (Ann Arbor, MI). Mice were housed in sterilized, ventilated 
microisolator cages and supplied with autoclaved commercial chow and sterile water. All 
mouse experiments were conducted in accordance with standard operating procedures 
approved by the University Committee on the Use and Care of Animals at the University of 
Michigan (Ann Arbor, MI). Tumorigenicity was determined by injecting breast cancer cells 
with Matrigel (BD Biosciences) into the #4 mammary fat pads of 6-week-old female NOD/
SCID mice with 5 to 6 mice per cohort. The animals were euthanized when the tumors were 
1.0–1.5 cm in diameter. A portion of each fat pad was fixed in formalin and embedded in 
paraffin for histologic analysis. Another portion was analyzed by the ALDH or CD24/CD44 
cytometric staining. For the nanovector experiments, SUM 159 cells (1 × 106) were injected 
into the fat pads of NOD/SCID mice. Four weeks later, the tumors grew to approximately 40 
to 60 mm3 at the injection site. Freshly prepared Lip-Tf-miR100 or LipA-Tf-NC containing 
25µg of miRNA mimics in 300 µL of 5% glucose was intravenously injected per mouse via 
the tail vein three times a week for a total of nine injections. The tumor sizes were measured 
twice a week with a caliper and calculated as tumor volume = length × width2/2. All animal 
experiments were performed in accordance with the University of Kansas (Lawrence, 
Kansas) guidelines for the care and use of animals.
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Chick chorioallantoic membrane invasion assays
Cell invasion by SUM159 (CTRL, miR100) in vivo was assessed using 11-day-old chick 
embryos in which an artificial air sac was created (21). SUM159 cells (CTRL, miR100) 
were labeled with DsRed (infected with DsRed-lentivirus). A total of 1 × 106 cells were 
inoculated atop the chick chorioallantoic membrane (CAM) for 3 days and the CAM was 
removed at the end of the incubation period. Tissues were fixed overnight in 4% 
paraformaldehyde and after an overnight incubation in 30% sucrose, CAM tissue was frozen 
in the optimum cutting temperature compound and cross sections were prepared for 
fluorescence microscopy. Invasion was quantified as a function of cell-associated 
fluorescence localized beneath the CAM surface (ImageQuant version 5.2; Molecular 
Dynamics, Inc.; ref. 21). To assess the distal metastasis of SUM159 (CTRL, miR100) cells, 
1 × 105 cells were injected intravenously at upper CAM and cultured for 5 days. Lower 
CAM was isolated after culture period and metastatic growth was examined.
Statistical analysis
Results are presented as the mean ± SD for at least three repeated individual experiments for 
each group using Microsoft Excel. Statistical differences were determined by using ANOVA 
and Student t test for independent samples. For the clinical specimens, all statistical analyses 
were carried out using SPSS 13.0 (SPSS). Spearman order correlation was applied to 
analyze the association between pairs between the expression of ALDH1 and miR100. 
Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank 
test. P < 0.05 in all cases was considered statistically significant.
Accession numbers
The GEO accession number for the gene expression of SUM159-miR100 ALDH+ and 
ALDH− cells from CTRL or doxycycline-treated groups reported in this article is 
GSE59361.
Results
miR100 expression is reduced in the ALDH+ population of breast cancer cells
We have previously demonstrated that primary human breast cancers and established breast 
cancer cell lines contain subpopulations with stem cell properties that can be isolated by 
virtue of their expression of ALDH as assessed by the Aldefluor assay. These cells display 
increased tumor-initiating capacity and metastatic potential compared with corresponding 
Aldefluor-negative cells (3). ALDH+ and ALDH− populations were separated from a human 
breast carcinoma cell line SUM159 and miRNAs were quantitated by expression profiling. 
miR100 expression is significantly higher in the ALDH− population compared with the 
ALDH+ population as shown in Fig. 1A A “bubble plot” can be used to depict both the 
abundance of a particular miRNA (given as the sum of the reads in the two populations) and 
its relative expression (plotted as a log2 of the ratio of reads in each population). As assessed 
by qRT-PCR, miR100 expression was variable across different breast cancer cell lines and 
did not correlate with molecular subtypes (Fig. 1B) and the ALDH+ cells were also shown in 
Supplementary Fig. S1 utilizing the Aldefluor assay. However, within each cell line, 
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miR100 expression was significantly increased in the ALDH− compared with ALDH+ cell 
population, including luminal (MCF7; Fig. 1C), basal (SUM149; Fig. 1D), and claudinlow 
(SUM159; Fig. 1E) cell lines. Similar findings were seen using cells isolated from primary 
human breast tumor xenografts (UM2, MC1, UM1), which were not passaged in vitro and 
directly established from patient tumors (Fig. 1F – H). MC1 and UM1 were derived from 
claudinlow and UM2 from a basal breast carcinoma (3). These studies demonstrate that in 
these breast cancer cell lines and primary xenografts, low miR100 expression is associated 
with the CSC phenotype characterized by increased ALDH expression.
miR100 overexpression decreases the cancer stem/progenitor population and inhibits 
cancer cell proliferation in vitro
We utilized a tetracycline (doxycycline) inducible miR100 construct tagged with RFP 
(pTRIPZ-mir-100-RFP) to determine the functional role of miR100 in CSCs (Fig. 2A). 
miR100 levels were significantly increased by 10 hours after doxycycline induction and 
maintained at a high level in the presence of doxycycline in all transduced cell lines (Fig. 
2A). Induction of miR100 resulted in a significant decrease in the proportion of CSCs as 
assessed by the Aldefluor assay, an effect seen in cell lines representing different breast 
cancer subtypes (Fig. 2B – D). In addition to its effect on the CSC population, induction of 
miR100 also inhibited cell proliferation in bulk tumor cells as assessed by MTT assay (Fig. 
2E – G and Supplementary Fig. S2D–S2F), an effect not due to the induction of apoptosis as 
assessed by Annexin V staining (Fig. 2H – J). In addition, the differentiation assay was 
performed for each cell line and ALDH+ cells took about 7 to 10 days to differentiate back 
to the parental cell level (Supplementary Fig. S3A–S3C). To determine the relationship 
between miR100 expression and cell-cycle kinetics, we utilized the doxycycline-inducible 
miR100 construct to determine the effect of miR100 induction on cell-cycle distribution. 
Induction of miR100 increased the G1 cell population from 57% to 76% in MCF7, from 
63% to 79% in SUM149 cells, and from 51% to 78% in SUM159 cells, with a concomitant 
decrease in the cycling population (S–G2–M). Furthermore, miR100 induces a G1 arrest in 
ALDH+ cell populations (Fig. 2K – N). This finding was confirmed by analysis of the 
cycling population as assayed by Ki67 staining (Fig. 2O). These experiments suggest that 
miR100 overexpression is able to reduce the CSC population as well inhibit growth of the 
bulk tumor population. Moreover, this is not due to the induction of apoptosis but due to the 
effect on the cell cycle. Furthermore, the decrease in the population of ALDH+ cells 
suggested a selective effect on the CSC population.
miR100 inhibits breast tumor growth in vivo
As the tetracycline-inducible miR100 system allows for the controlled regulation of CSC 
populations, it provides a valuable tool for assessing the role of CSCs in tumor growth in 
mouse xenograft models. Furthermore, the ability to regulate the CSC population during 
different phases of tumor growth allows for the assessment of the role of these cells in tumor 
initiation and maintenance. We first determined the effect of miR100 induction on the 
growth of established tumors. When tumors reached 0.2 to 0.3 cm in diameter, we induced 
miR100 with doxycycline treatment (hereafter “miR100 late”). Induction of miR100 
significantly inhibited the growth of SUM159 (Fig. 3A), SUM149 (Supplementary Fig. 
S4A), MCF7 (Supplementary Fig. S4C), and T47D (Supplementary Fig. S4D) xenografts. 
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After 6 to 10 weeks of treatment, animals were sacrificed and cell proliferation (Ki67 
staining) and CSC populations were assessed. Induction of miR100 reduced the Aldefluor-
positive population by more than 90% in SUM159 (Fig. 3B) and more than 30% in SUM149 
(Supplementary Fig. S4B) compared with control. Cell proliferation as assessed by Ki67 
expression was quantitated by immunohistochemistry in the tumor specimens from SUM159 
xenografts. Consistent with retarded tumor growth, the proportion of Ki67-positive cells was 
significantly lower in the miR100 late group compared with the control group (Fig. 3C). 
miR100 expression was significantly higher in doxycycline-treated group compared with the 
control group at the end of treatment (Supplementary Fig. S5). To assess the effect of 
miR100 induction on the CSC population, we determined the ability of serial dilutions of 
cells obtained from primary tumors to form tumors in secondary NOD/SCID mice. Cells 
isolated from tumors with miR100 induction had markedly reduced tumor-initiating capacity 
in secondary mice with no tumors observed after the introduction of 50 cells from the 
miR100 late group (Fig. 3D). These functional assays allow us to calculate the frequency of 
tumor-initiating cells. miR100 expression decreases the CSC frequency (22) supporting the 
results from Aldefluor analysis (Fig. 3E). Interestingly, we found that the percentage of 
ALDH+ cells in both primary CTRL and secondary CTRL tumors were increased compared 
with the parental cells injected (Supplementary Fig. S6). These studies demonstrate that 
miR100 induction reduces the CSC population, reducing growth of established tumor 
xenografts.
Preclinical models have suggested that CSCs play a role in tumor recurrence and metastasis 
following adjuvant therapy (23). This suggests that targeting of CSCs may have more 
dramatic effects with early treatments than with late treatments. To model this, we induced 
miR100 immediately after tumor cell implantation ("miR100 early"). Although tumors grew 
after 2 to 3 weeks after orthotopic induction in control animals of SUM159 cells, there was 
no observed tumor growth at 16 weeks after miR100 induction (Fig. 3A). Similar finding 
was seen in MCF7 and T47D xenografts (Supplementary Fig. S4C and S4D) and three 
additional primary breast tumor xenografts UM2, MC1, and UM1 (Fig. 3F – H). Utilizing 
qRT-PCR, we confirmed that miR100 level was significantly higher in the miR100 groups 
(late and early) compared with control (Supplementary Fig. S7). Furthermore, to simulate 
the adjuvant setting in clinic, we induced miR100 and/or administered docetaxel 
immediately after tumor cell implantation. Although tumors grew after 4 to 5 weeks in 
control animals, there was no observed tumor growth following miR100 induction and/or 
docetaxel treatments for 8 weeks (Supplementary Fig. S8). After 8 weeks, treatments were 
stopped and animals observed for an additional 4 weeks (except for the control group, which 
had to be sacrificed). In SUM159 xenografts, tumors developed in all mice who received 8 
weeks of docetaxel alone. In contrast, there was minimal tumor growth in animals with 
previous miR100 induction, independent of whether they had received docetaxel 
(Supplementary Fig. S8). Together, these studies support the concept that inhibiting CSC 
immediately after implantation, simulating the adjuvant setting, has a profound effect on 
inhibiting subsequent tumor growth.
Recently, we developed tumor-specific, ligand-targeting, self-assembled nanoparticle-DNA 
lipoplex systems designed for systemic gene therapy of cancer (24–28). CD44 is 
preferentially expressed in breast CSCs, so we employed anti-CD44 monoclonal antibody 
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H4C4 (29) and anti-CD44 scFv (30) in liposome–DNA complex to make nanovectors in our 
study, which has been tested both in vitro and in vivo. Our study showed that systemic 
miR100 delivery with anti-CD44 nano-vectors inhibits the tumor growth of SUM159 in 
NOD/SCID mice (Fig. 3I). This study further confirms the antitumor capability of miR100 
in vivo.
To determine whether downregulation of endogenous miR100 in SUM159 cells promoted 
tumorigenesis, we utilized a mirZip antisense miRNA. qRT-PCR was utilized to confirm the 
efficient knockdown of miR100 (Supplementary Fig. S9A). miR100 knockdown 
significantly increased SUM159 cell proliferation as accessed by the MTT assay 
(Supplementary Fig. S9B). As shown in Supplementary Fig. S9C, knockdown of miR100 
significantly promoted the growth of SUM159 cells in tumor xenografts as well as increased 
the CSC frequency (Supplementary Fig. S9D).
miR100 inhibits tumor metastasis in vivo
Previous studies have demonstrated that CSCs mediate invasion and metastasis. To 
determine the effect of miR100 expression on tumor invasion, we utilized the CAM invasion 
assay. SUM159 CTRL or SUM159 miR100 were labeled with DsRed and cultured atop the 
chick CAM, a tissue whose stromal compartment is rich in interstitial collagens (31). After a 
3-day culture period, control SUM159 cells rapidly cross the CAM surface and infiltrate the 
underlying stromal tissues (Fig. 4A). SUM159 cells not only infiltrate the upper CAM 
surface but also access the chick vascular bed to travel to distant sites in the embryo (Fig. 
4B). However, both invasion and intravasation of SUM159 cells were dramatically inhibited 
by miR100 overexpression (Fig. 4A, B).
To determine whether the expression of miR100 affects development of tumor metastasis in 
a mouse model, SUM159 cells cotransfected with the inducible miR100 vector and 
luciferase were introduced into NOD/SCID mice by intracardiac injection, and metastasis 
formation was monitored by bioluminescence imaging. Doxycycline treatment was initiated 
after intracardiac injection. As shown in Fig. 4C, miR100 induction completely suppressed 
metastasis formation, which was confirmed by histologic examination with pan-cytokeratin 
staining (Fig. 4C). To determine whether miR100 induction in ALDH+ cells alters their 
metastatic capacity, we sorted ALDH+ cells and ALDH− cells, and introduced them into 
NOD/SCID mice by intracardiac injection. Doxycycline treatment was initiated after 
intracardiac injection. We found that the miR100 induction completely blocked metastasis 
of ALDH+ cells in addition to the unsorted total population in these mice (Supplementary 
Fig. S10). Furthermore, we confirmed our previous findings that ALDH+ cells had much 
higher metastasis capability than the unsorted total population, but ALDH− cells barely 
metastasized (Supplementary Fig. S10). Together, these studies suggest miR100 expression 
inhibits CSC invasion as well as growth at metastatic sites.
miR100 downregulates stem cell regulatory and cell proliferation genes
To determine the cellular targets of miR100 in BCSCs and non-BCSCs, ALDH+ and 
ALDH− populations of pTRIPZ-SUM159-miR100 cells were separated and cultured in 
suspension for 10 hours in the presence or absence of doxycycline. Gene expression profiles 
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of the four populations were determined utilizing Affymetrix microarrays (Supplementary 
Fig. S11A). Of the 6,900 genes downregulated at least 2-fold upon doxycycline treatment in 
the ALDH+ population, 18 overlapped with the 40 predicted target sequences of miR100 
from TargetScan including genes known to be involved in stem cell regulation and cell 
proliferation (Supplementary Fig. S11A), including SMARCA5, SMARCD1, BMPR2, FGFR, 
FZD5, and IFGR. The downregulation of SMARCA5, SMARCD1, and BMPR2 in the 
ALDH+ population of MCF7, SUM149, and SUM159 cells after miR100 induction was 
confirmed with qRT-PCR (Supplementary Fig. S11B–S11D). SMARCA5 was 
downregulated in SUM159 and SUM149 cells and BMPR2 was only downregulated in 
SUM159 cells after miR100 induction. Downregulation of SMARCD1 and SMARCA5 
protein by miR100 induction was confirmed by Western blot analysis (Fig. 5A). In contrast, 
only 560 genes were significantly downregulated by doxycycline in the ALDH− population 
(Supplementary Fig. S11A) with three of these genes overlapping with predicted miR100 
targets. These studies suggest that miR100 regulates the CSC population and inhibits cell 
proliferation by simultaneously targeting a number of stem cell regulatory genes and cell 
proliferation genes. To confirm these findings, we utilized a luciferase reporter assay to 
determine the effect of miR100 on the expression of the stem cell regulatory genes 
SMARCD1, SMARCA5, and BMPR2 selected from the expression profiling data. Expression 
of miR100 reduced the activities of SMARCD1 in MCF7 (Fig. 5B), SMARCD1 and 
SMARCA5 in SUM149 (Fig. 5C), SMARCD1, SMARCA5, and BMPR2 in SUM159 cells 
(Fig. 5D).
To determine whether SMARCA5, SMARCD1, and BMPR2 represent functionally important 
targets of miR100, we knocked down these genes individually or in combination in 
SUM159 cells and confirmed knockdown by qRT-PCR for BMPR2 and Western blot 
analysis for SMARCD1 and SMARCA5 (Supplementary Fig. S12A). Knocking down any 
of these genes individually inhibited cell proliferation, whereas knockdown of all three 
genes together had most dramatic effect on the inhibition of cell proliferation 
(Supplementary Fig. S12B). Furthermore, knockdown of SMARCD1 and SMARCA5 
significantly decreases the proportion of ALDH+ SUM159 cells, suggesting these genes play 
a role in the regulation of CSC self-renewal (Supplementary Fig. S12C). To determine 
whether knockdown of these genes inhibited tumorigenesis, we injected serial dilutions of 
SUM159 control, SUM159 SMARCD1-SMARCA5-shRNAs, and SUM159 SMARCD1-
SMARCA5-BMPR2-shRNAs into the mammary fat pads of NOD/SCID mice. Knockdown 
of SMARCA5 and SMARCD1 significantly retarded tumor growth and decreased the 
proportion of BCSCs in these tumors (Supplementary Fig. S12D). "Rescue" experiments 
where either SMARCA5 or SMARCD1 was overexpressed using a cDNA that lacked the 3′-
UTR containing the miR100-binding sites, which was verified by Western blot analysis as 
shown in Supplementary Fig. S13, partially abrogated miR100-mediated decrease of 
ALDH+ cell population (Fig. 5E), and partially abrogated miR100-mediated inhibition of 
cell proliferation (Fig. 5F) as well as inhibition of tumor growth of SUM159 cells (Fig. 5G) 
by partially abrogating miR100-mediated decrease of ALDH+ cell population in the tumors. 
Similar results were also seen in another breast cancer cell line SUM149 in vitro 
(Supplementary Fig. S14). Together, these results strongly support the role of SMARCA5 
and SMARCD1 as direct and functional targets of miR100. Furthermore, to understand the 
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clinical significance of both SMARCA5 and SMARCD1 in breast cancer, we examined the 
relationship between expression of SMARCA5 or SMARCD1 and overall survival of 
patients in publically available datasets (32, 33). Utilizing the Kaplan–Meier method, we 
determined that breast tumors with high SMARCA5 or SMACD1 expression had a 
significantly shorter survival time, compared with those with low expression 
(Supplementary Fig. S15). This supports the clinical relevance of our in vitro and mouse 
studies.
Low miR100 expression in primary breast cancer tissues correlates with high ALDH1 
expression and poor patient survival
To investigate the clinical significance of miR100 expression, we determined the 
relationship between expression of miR100, ALDH1, and patient survival in a cohort of 94 
patients with breast cancer. We utilized immunohistochemical staining to assess ALDH1 
expression and ISH with a digoxigenin-labeled miR100 probe to assess miR100 expression 
in primary breast cancer tissues of patients with different molecular subtypes of breast 
cancer (Supplementary Table S1) as well as in normal breast tissue (benign). As shown in 
Fig. 6A, ALDH1 expression was very low in normal breast and in stages I and II and 
dramatically increased in invasive breast cancer, whereas previously reported ALDH 
expression correlated with tumor grade (Fig. 6A and Supplementary Table S2).In contrast, 
miR100 level was very high in normal breast and ductal carcinoma in situ tumors, and was 
decreased in invasive tumors where its expression was inversely related to tumor stage (Fig. 
6A). Expression of miR100 and ALDH1 were inversely correlated (R = −0.334; P = 0.001) 
with low expression of miR100 positively related to high expression of ALDH1 (Fig. 6B). 
Kaplan–Meier survival curves demonstrated that the overall survival of the patients with 
high miR100 expression was significantly longer than those with low miR100 expression 
(Fig. 6C; P < 0.05).
Discussion
Accumulating evidence suggests that more effective therapies of cancer will require the 
successful targeting of CSC populations. However, it is still not fully understood how these 
CSCs are regulated. Previous studies show that both miRNA Let7 and mir200c regulates 
self-renewal of breast stem cells (34, 35). These miRNAs offer great promise for cancer 
therapy as they might have potential to target the CSCs. Thus, miRNA therapy could be a 
powerful tool to address CSC dysregulation and its resulting self-renewal and cancer 
progression in patients.
In this study, we demonstrate that miR100 is capable of modulating BCSC self-renewal and 
inhibiting breast cancer cell proliferation through targeting SMARCA5, SMARCD1, and 
BMPR2 both in vitro and in vivo in addition to the Wnt/β-catenin pathway. Enforced 
miR100 expression in breast cancer cell lines and primary xenografts significantly reduced 
the tumor growth by reducing CSC populations in vivo. These studies are consistent with 
one recent finding (36); however, they mainly used one immortalized transformed HMLE in 
this study. CSC models predict that the efficacy of CSC-targeting agents should be most 
pronounced in the early setting where tumor growth from micrometastasis is dependent on 
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stem cell self-renewal (37). Consistent with this model, induction of miR100 immediately 
after fat pad implantation or after development of micrometastasis by intracardiac injection 
completely blocked tumor initiation and metastasis. These studies suggest that miR100 
inhibits tumor growth and metastasis by inhibiting BCSC self-renewal and cell proliferation. 
Our studies differ from a recent report suggesting that miR100 regulates cancer cell 
proliferation by targeting IGF2 (38). Our studies did not show IGF2 was significantly 
affected in either stem cell population or non–stem cell population by overexpression of 
miR100. Instead, we found that a majority of genes downregulated by miR100 
overexpression were seen in ALDH+ population, including genes known to be involved in 
stem cell self-renewal and cell proliferation, including SMARCA5, SMARCD1, BMPR2, and 
FZD5. It has been shown that miR100 was required for proper differentiation of mouse 
ESCs and that it functions in part by targeting SMARCA5 (39). SMARCA5 (hSNF2H) is a 
member of SWI/SNF family, containing helicase and ATPase activities. It is overexpressed 
in ovarian cancer where it promotes tumor growth (40). SMARCD1 (BAF60a) is also a 
member of SWI/SNF family of proteins and regulates cell proliferation. In this study, we 
confirmed that both SMARCA5 and SMARCD1 are direct targets of miR100 and 
demonstrated that the miR100 represses the expression of SMARCD1 and SMARCA5 at 
both mRNA and protein level, and that both are involved in mediating the effects of miR100 
on CSC self-renewal and cancer cell proliferation. Furthermore, previous studies showed 
that SWI/SNF family members interact with the components of the Wnt signaling pathway, 
resulting in decreased Wnt signaling (41). Previous work indicates that telomerase catalytic 
subunit [human telomerase reverse transcriptase (hTERT)] regulates stem cell homeostasis 
independent of its function at telomeres (42) and that TERT, together with the SWI/SNF 
complex protein brahma-related gene 1 (BRG1, also called SMARCA4), modulates stem 
cell homeostasis by modulating the WNT/β-catenin signaling pathway (43). In that system, 
telomerase directly modulates Wnt/β-catenin signaling by serving as a cofactor in a β-
catenin transcriptional complex where the telomerase protein component TERT interacts 
with BRG1 activating Wnt signaling. Furthermore, chromatin immunoprecipitation of the 
endogenous TERT protein from mouse gastrointestinal tract demonstrated that TERT 
physically occupies gene promoters of Wnt-dependent genes (43). Our previous studies 
showed that the Wnt/β-catenin pathway is an important regulator of BCSC self-renewal 
(44). The observation that miR100 expression leads to a decrease in both proportion and 
absolute number of BCSCs indicates an inhibitory effect on CSC self-renewal, resulting in a 
depletion of this cell population. In addition to SWI/SNF proteins, our profiling data also 
demonstrated that miR100 targets the Wnt receptor FZD5, the significance of which requires 
further investigation. Together, these studies suggest that miR100 inhibits BCSC self-
renewal primarily by targeting SWI/SNF family members. A recent report suggested that the 
tumor-inhibiting properties of miR100 were not due to depletion of the stem-like population 
(34). However, these studies assessed CSCs solely by expression of the CSC marker 
ALDH1. In contrast, our studies utilized functional CSC assays as well as the Aldefluor 
assay, which measures total ALDH activity and is not limited to the ALDH1 isoform.
As determined by ISH, we found that miR100 was expressed at the highest level in normal 
breast tissue with progressively less expression in advanced invasive breast carcinoma. In 
these tumors, there was a strong inverse correlation between miR100 expression and the 
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expression of CSC marker ALDH1 (P = 0.002). We also found a significant association (P = 
0.039) between low miR100 expression and decreased patient overall survival. Our results 
are consistent with a previous report showing that miR100 expression was decreased in 
advanced and metastatic prostate cancer relative to normal prostate epithelium (45, 46) and 
in invasive human breast tumors compared with benign patient samples (38).
In conclusion, these data demonstrate that miR100 modulates BCSCs and cancer cell 
proliferation via targeting SMARCA5 and SMARCD1, in addition to BMPR2 signaling 
pathways. The tetracycline-inducible miR100 system allows for controlled regulation of the 
CSC population, providing a valuable model to simulate the effects of CSC-directed 
therapies on breast cancer growth and metastasis. Furthermore, pathways regulated by 
miR100 may provide novel targets for CSC-directed therapies.
Our miR100 anti-CD44 nanovector studies provide novel technique that can deliver miR100 
to breast CSCs and inhibit their self-renewal and tumor initiation, which will provide an 
important impetus to develop the anti-CD44-nanovector-miR100 as a novel and more 
effective therapy for human breast cancer by modulating BCSCs. Furthermore, pathways 
regulated by miR100 may provide novel targets for CSC-directed therapies.
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Comparison of miR100 expression in different cell populations. A, a bubble plot depicting 
the relative abundance and log2 ratio of miRNAs in SUM159 cells. B, miR100 expression 
level was measured indifferent cell lines by qRT-PCR. ALDH+ cells from MCF7 cells (C), 
SUM149 cells (D), SUM159 cells (E), or primary breast tumor xenografts UM2 (F), MC1 
(G), and UM1 (H) show lower miR100 expression level in comparison with ALDH− cells 
from the same cell lines as accessed by qRT-PCR. * P < 0.05. Error bars, mean ± SD.
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miR100 overexpression decreases ALDH+ population and inhibits cell proliferation. A, 
diagram of miR100-inducible lentiviral vector (left). Different cell lines were transduced 
with the pTRIPZ-miR100 lentivirus and selected with puromycin for 7 days. Cells were 
treated with (miR100) or without (CTRL) tetracycline (doxycycline; DOX). Total RNA was 
isolated and miR100 expression level were measured by qRT-PCR. B-D, transduced cells 
were treated with vehicle control or doxycycline (1µg/mL) for 7 days, and dissociated and 
utilized for Aldefluor assay by flow cytometry [MCF7 (B), SUM149 (C), SUM159 (D)]. E-
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G, 200–500 transduced cells were seeded in 96-well culture plates and cultured in the 
absence (CTRL) and presence (miR100) of doxycycline for 3,5, or 7 days. MTT assays were 
conducted following the manufacturer’s protocol and the optical density (OD) value was 
measured at 590 nm. H-O, transduced cells were treated with vehicle control or doxycycline 
(1µg/mL) for 7 days. Cells were dissociated and stained for Annexin V-APC and DAPI for 
apoptosis assay by flow cytometry (H-MCF7, I-SUM149, J-SUM159), and utilized for cell 
cycle by flow cytometry [MCF7 (K), SUM149 (L), SUM159 (M and N)]. Propidium iodide 
staining was used to analyze cell-cycle distribution. miR100 induction resulted in an 
increased proportion of cells in the G1 phase. O, ALDH+ cells were sorted from transduced 
SUM159 cells (CTRL and miR100) by Aldefluor assay, cytospun, and stained for Ki67 by 
immunohistochemical staining. Both Ki67+ tumor cells and Ki67− tumor cells were counted 
in at least five random fields. miR100 induction significantly decreased Ki67+ cells in 
ALDH+ cell populations. *, P< 0.05. Error bars, mean ± SD.
Deng et al. Page 17














miR100 inhibits tumor growth of SUM159 cells in vivo. A, 50,000 pTRIPZ-SUM159-
miR100 cells were injected into the fourth fat pads of NOD/SCID mice. The treatment 
started as indicated on the top of the growth curve. miR100 was induced by adding 
doxycycline (DOX, 1 mg/mL) in drinking water. miR100 late, doxycycline was added to the 
drinking water after the average tumor size reached to about 10 mm3; miR100 early, 
doxycycline was added to the drinking water right after SUM159 cells were inoculated to 
the fat pads. miR100 induction inhibits SUM159 tumor growth in advance setting and 
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completely blocks tumor formation in adjuvant setting. B, tumors from CTRL and miR100 
(late) were collected and cells were isolated from each tumor. ALDH was accessed by the 
Aldefluor assay on viable dissociated cells. C, Ki67 stainings were performed by 
immunohistochemistry on fixed sections; both Ki67+ cells (brown) and Ki67− tumor cells 
were counted in at least five random fields. D, serial dilutions of cells obtained from CTRL 
and miR100 (late) were implanted in the fourth fat pads of secondary mice, which received 
no further treatment. E, extreme limiting dilution analysis for the group CTRL or miR100 
(late) was calculated on the website http://bioinf.wehi.edu.au/software/elda/. Briefly, 
utilizing the online calculation form, we input the number of cells injected and the number 
of mice used in each group and compared the CSC frequency between CTRL group and 
miR100 group. F-H, fresh isolated cells from human primary breast tumor xenografts (UM2, 
MC1, UM1) were infected with pTRIPZ-miR100 lentivirus in suspension and doxycycline 
was added to the medium for 1 to 2 days and RFP-positive cells were collected. A total of 
100,000 cells from noninfected tumor cells or pTRIPZ-UM2 (F), MC1 (G), or UM1 (H) -
miR100 cells was injected into the fourth fat pads of NOD/SCID mice. The treatment started 
right after injection as indicated on the top of the growth curve. miR100 was induced by 
adding doxycycline (1 mg/mL) in drinking water. *, P< 0.05; Error bars, mean ± SD. I, 
NOD/SCID mice bearing SUM159 xenografts were treated with either Tf-LipA-negative 
control (Nano-NC2) or Tf-LipA-miR100 (Nano-miR100; n = 8 mice per cohort) by tail vein 
injection at a dose of 25 µg miRNA mimics per mouse every other day (EOD). Treatment 
with miR100 anti-CD44 nanovector significantly inhibited tumor growth (P < 0.01) 
compared with the negative control group. Data, the tumor volume before initiation of 
treatment.
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miR100 inhibits metastasis of SUM159 cells in vivo. A, SUM159 cells (CTRL, miR100) 
were labeled with DsRed (infected with DsRed lentivirus) and cultured atop the live chick 
CAM for 3 days. CAM sections were stained with anti-chicken type IV collagen antibody 
for basement membrane and blood vessels (green) and counterstained with DAPI. The CAM 
surface is marked by dashed white lines, and CAM invasion was quantified as described in 
Materials and Methods. Results are expressed as the means ± SEM (n = 3). * P < 0.01. Bars, 
100 µm. B, fluorescence micrograph of cells metastasizing to the distant organ sites. C, 
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200,000 pTRIPZ-SUM159-miR100-Luc cells in 100 µL of PBS were injected into the left 
ventricle of NOD/SCID mice. The treatment started immediately after injection as indicated 
by the red arrow. Metastasis formation was monitored using bioluminescence imaging. 
Quantification of the normalized photon flux, measured at weekly intervals following 
inoculation. Histologic confirmation (right) by pan-cytokeratin (AE1/AE3) staining (brown) 
of metastasis in bone and soft tissues resulting from the CTRL or miR100 group of mice. 
The metastasis was suppressed by miR100 overexpression. * P < 0.05. Error bars, mean ± 
SD.
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SMARCA5 and SMARCD1 are direct and functional targets of miR100. A, targets 
(SMARCA5 and SMARCD1) are verified by Western blot analysis in all three cell lines. B–
D, activity of the luciferase gene linked to the 3′ UTR of SMARCD1, SMARCA5, or 
BMPR2. The pMIR-REPORT or LightSwitch 3′ UTR luciferase reporter plasmids were 
transiently transfected into pTRIPZ-miR100 cell lines [MCF7 (B); SUM149 (C); SUM159 
(D)]and an internal control ACTB luciferase reporter was cotransfected for normalization. 
The relative luciferase activity was calculated as the ratio of the results from the cells 
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transfected by individual reporter/the results from the cells transfected by the internal 
control in the same cell group. The data are mean and SD of separate transfections (n = 4). E 
and F, overexpression of human SMARCA5 and SMARCD1 lacking 3′ UTR partially 
overcome the decrease of ALDH+ cells and the inhibition of cell proliferation by miR100 
induction in SUM159 cells. G, overexpression of human SMARCA5 and SMARCD1 
lacking 3′ UTR partially overcome the inhibition of tumor growth by miR100 induction in 
SUM159 cells. Fifty thousand cells from different groups were injected into the fourth fat 
pads of NOD/SCID mice. The treatment was started when the tumors reached to the average 
size of 10 mm3 in the control group and the treatment lasted for 8 weeks. miR100 was 
induced by adding doxycycline (DOX, 1 mg/mL) in drinking water. At the end of the 
treatment, the tumors were taken out and the tumor images (left) and tumor size (right) are 
shown. H, overexpression of human SMARCA5 and SMARCD1 lacking 3′ UTR partially 
overcome the decrease of ALDH+ cells by miR100 induction in SUM159 tumors. Cells 
were isolated from each tumor collected in G and ALDH was accessed by the Aldefluor 
assay on viable dissociated cells. * P < 0.05 (compared with the corresponding parental 
group); &, P < 0.05 (compared with the corresponding CTRL group). Error bars, mean ± 
SD.
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Expression of ALDH1 and miR100 in breast carcinoma. A, representative example of 
ALDH1 (DAB-IHC, 400×; top, brown) and miR100 (NBT/BCIP-ISH, 400×; bottom, blue) 
in normal breast and breast tumor (stage I, II, III, IV). Black arrow, ALDH1; white arrow, 
miR100. B, the correlation analysis of miR100 and ALDH1 expressions: the expressions of 
miR100 and ALDH1 are negatively correlated (R = −0.335; P = 0.002). The low expression 
of miR100 was positively related to the high expression of ALDH1. C, Kaplan-Meier curves 
with log rank tests show statistical difference in overall survival: the red full line and the 
blue dotted line represent the high and low expression of miR100, respectively. It shows that 
the 5-year survival rates were shorter in patients with low expression of miR100 (P = 0.039).
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